EMA/515517/2013

# European Medicines Agency decision

P/0205/2013

of 3 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for alipogene tiparvovec (Glybera), (EMEA-000292-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

# European Medicines Agency decision

P/0205/2013

of 3 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for alipogene tiparvovec (Glybera), (EMEA-000292-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/119/2008 issued on 1 December 2008,

Having regard to the application submitted by uniQure biopharma B.V. on 23 April 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 July 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

***Article 1***

Changes to the agreed paediatric investigation plan for alipogene tiparvovec (Glybera), solution for injection, intramuscular use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

***Article 2***

This decision is addressed to uniQure biopharma B.V., Meibergdreef 61, 1105 BA – Amsterdam, The Netherlands.

Done at London, 3 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/267221/2013

# Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000292-PIP01-08-M01

## Scope of the application

**Active substance(s):**

Alipogene tiparvovec

**Invented name:**

Glybera

**Condition(s):**

Treatment of hyperchylomicronaemia

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Solution for injection

**Route(s) of administration:**

Intramuscular use

**Name/corporate name of the PIP applicant:**

uniQure biopharma B.V.

**Information about the authorised medicinal product:**

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

## Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, uniQure biopharma B.V. submitted to the European Medicines Agency on 23 April 2013 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/119/2008 issued on 1 December 2008.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 22 May 2013.

## Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified, some measures have been added.

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report :

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 19 July 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

# Annex I

# The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

# 1. Waiver

## *1.1. Condition: Treatment of hyperchylomicronaemia*

The waiver applies to:

- The paediatric population from birth to less than 2 years of age;
- for solution for injection, for intramuscular use;
- on the grounds that the specific medicinal product is likely to be unsafe.

# 2. Paediatric Investigation Plan

## *2.1. Condition: Treatment of hyperchylomicronaemia*

### 2.1.1. Indication(s) targeted by the PIP

Treatment of lipoprotein lipase deficiency

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age.

### 2.1.3. Pharmaceutical form(s)

Solution for injection, for intramuscular use.

### 2.1.4. Measures

| Area | Number of measures | Description |
|---|---|---|
| Non-clinical | 5 | • Study 1: Pharmacology study of a comparison of the level and persistence of lipoprotein expression in young and mature mice<br>• Study 2: Pilot study of biodistribution and germ line transmission in juvenile mice<br>• Study 3: Toxicity and biodistribution study in immature mice<br>• Study 4: Exploratory toxicity/efficacy study in mice and cynomolgus macaques<br>• Study 5: Juvenile toxicity study in mice |
| Clinical | 2 | • Study 6: LPLD Registry: observational, multicentre, longitudinal pharmaco-epidemiologic study in lipoprotein lipase-deficient (LPLD) patients, either treated or not treated with alipogene tiparvovec<br>• Study 7: Open label, single dose, uncontrolled trial to evaluate safety and efficacy of alipogene tiparvovec in children from 2 to less than 18 years of age diagnosed with lipoprotein lipase deficiency |

## 3. Follow-up, completion and deferral of PIP

| | |
|---|---|
| Concerns on potential long term safety and efficacy issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By December 2021 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |

# Annex II

# Information about the authorised medicinal product

## Condition(s) and authorised indication(s):

1. Hyperchylomicronaemia

   Authorised indication(s):

   - Glybera is indicated for adult patients diagnosed with familial lipoprotein lipase deficiency (LPLD) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. The diagnosis of LPLD has to be confirmed by genetic testing. The indication is restricted to patients with detectable levels of LPL protein (see section 4.4).

## Authorised pharmaceutical form(s):

Solution for injection.

## Authorised route(s) of administration:

Intramuscular use.